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Short Summary 28 
Since the approval of the HPV vaccine by the FDA in June 2006, there have been statistically 29 
significant declines in diagnoses of high grade cervical intraepithelial neoplasia in women ages 30 
21-24 in the state of Connecticut across race, ethnicity, and socioeconomic status with respect to 31 
the federal poverty line.  This downward trend remains statistically significant across all three 32 
sociodemographic factors in women ages 21-24 after adjusting incidence rates to account for only 33 
women who have undergone cervical pap smears.  34 
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Background:  In 2006, the FDA approved the first vaccine against human papillomavirus.  Trends 53 
in HPV-related sequalae are an effective method of analyzing HPV vaccine impact.  Our primary 54 
objective was to measure trends in cervical neoplasia based on sociodemographic characteristics 55 
including race, ethnicity, and socioeconomic status.   56 
Methods:  Since 2008, Connecticut has required reporting of cervical intraepithelial neoplasia 57 
labeled grade 2+ and adenocarcinoma in situ.  CIN 2+ diagnoses trends were modeled by area-58 
based measures of age, race, ethnicity, and socioeconomic status using negative binomial 59 
regression and change-point analysis. Incidence rate measurements were adjusted to reflect 60 
inclusion of women who had completed cervical pap smears.   61 
Results:  From 2008-2017 incidence rate of cervical intraepithelial neoplasia per 100,000 person-62 
years declined by 65-85% in 21-26-year-old women.  After adjusting by BRFSS data incidence 63 
rate declines only remain significant in women ages 21-25 with diagnoses dropping from 30-80%.  64 
Significant declines were demonstrated across sociodemographic factors.  Women ages 21-24 65 
showed significant declines in CIN 2+ regardless of what percentage of the population in their 66 
census tract identified as Black, Latino, or below the federal poverty line.  From 2008-2017 the 67 
incidence rate of cervical intraepithelial neoplasia per 100,000 person-years declined by 73-76% 68 
across all census tracts, regardless of what percentage of the population in their census tract 69 
identified as Latino (i.e. less than 5%, 5-10%, 10-20%, and greater than 20%).  For area-based 70 
measures of racially identifying as Black the decline was 75-77%.  Lastly, for area-based measures 71 
of identifying as below the federal poverty line the decline was 71-78%.  When data was adjusted 72 
for screening population using BRFSS data the results were as follows:  66-69% decline in 73 
incidence rate of CIN 2+ across area-based measures of racially identifying as Black, 63-68% 74 
decline in incidence rate across area-based measures of identifying as Latino, and 62-70% decline 75 
in incidence rate across area-based measures of identifying as below the federal poverty line.   76 
Conclusions:  Significant declines in CIN+2 diagnoses from 2008-2017 were observed in the 77 
overall population and amongst the estimated screened population. These trends are suggestive of 78 
declines attributable to HPV vaccination in CT.  The significant decline in incidence across 79 
different sociodemographic factors, even after stratifying census tracts by the portion of their 80 
populations that identify as Black, Latinx, or below the federal poverty line (FPL) demonstrates 81 
that vaccine impact is reaching various sociodemographic groups and reduces risk of results 82 
confounding by race, ethnicity, and socioeconomic status. 83 
Introduction 84 
In 2006, the Federal Drug Administration (FDA) approved a quadrivalent HPV vaccine 85 
developed for girls aged 9 to 26.  The vaccine provided immunity against the four most common 86 
HPV strains, 6, 11, 16 and 181.  Approximately 66% of cervical cancer cases are attributable to 87 
HPV-16 & HPV-182. HPV-6 and HPV-11 are responsible for over 90% of anogenital warts cases2. 88 
The CDC’s Advisory Committee on Immunization Practices (ACIP) recommends administration 89 
of the HPV vaccine to all young girls ages 11-12 and catch up vaccination schedules for girls ages 90 
13-263.  The vaccine was initially administered in 3 doses over a 6-month time period.   91 
The HPV vaccine has been modified in content and implementation efforts since initial 92 
approval in 2006.  In 2009 the vaccine was approved for use in boys ages 9-26 to provide immunity 93 
against HPV related sequalae such as anogenital warts and anal & penile cancers.  This change in 94 
FDA approval was followed by recommendations from the ACIP in 2011 to vaccinate all boys 95 
ages 11-12 and perform catch up vaccination schedules in boys ages 13-21.  In 2014 the vaccine 96 
was changed to a nonvalent format providing additional coverage against HPV strains 31, 33, 45, 97 
52, and 583.  In 2016 clinical guidelines were changed to recommend a 2-dose schedule for all 98 
youth ages 9-14.  In October 2018 the FDA approved use of the HPV vaccine for immunization 99 
of all men and women ages 27-453.  However, this approval is not currently supported by ACIP 100 
recommendations.  There is growing interest in researching the impact of HPV vaccination on 101 
HPV related sequalae including incidence of anogenital warts, precancerous lesions, and cancer 102 
diagnoses4,5. 103 
 The Connecticut Emerging Infections Program, a collaboration between the Connecticut 104 
Department of Public Health and the Yale School of Public Health, has engaged in active, 105 
population-based surveillance of HPV pre-cancerous cervical lesions since 2008 6.  The decision 106 
was made to support efforts from the Centers for Disease Control & Prevention (CDC) to monitor 107 
the impact of HPV vaccination uptake on HPV related sequelae.  The efforts of EIP reflect similar 108 
endeavors performed elsewhere in the United States 7,8, Australia 9,10,11, Canada12, and Denmark13.   109 
In 2008 the Connecticut Department of Public Health began requiring reporting of all 110 
cervical intraepithelial lesions grade 2 or higher and adenocarcinoma in situ (collectively referred 111 
to as CIN 2+) to ensure complete case ascertainment.  Over the past several years, HPV-IMPACT 112 
has identified temporal trends in CIN 2+ incidence to assess the impact of the HPV vaccine and 113 
compared these changes with shifts in sexual behavior, STI prevalence, and frequency of Pap 114 
smear screenings 6.  The latter is of particular importance due to recent changes in cervical cancer 115 
screening clinical guidelines.  Prior to 2012, clinical guidelines from the U.S. Preventive Services 116 
Task Force (USPSTF) recommended that women ages 21-29 undergo annual Pap smears. After 117 
2012, women ages 21-29 were recommended cytology (Pap smear) testing alone every 3 years 118 
(instead of annually).  Women ages 30-65 were given the same recommendation and additionally 119 
offered the alternative recommendation of cytology and HPV testing every 5 years 14.  As of 2018, 120 
clinical guidelines have changed again.  New recommendations provide women ages 30-65 with 121 
three options.  They can engage in cytology testing alone every 3 years, high risk HPV testing 122 
alone every 5 years, or cytology testing in conjunction with high risk HPV testing every 5 years 123 
15.  The 2012 change from recommending Pap smears annually to triennially may risk confounding 124 
declines in diagnoses of CIN 2+ lesions by conflating decreased screening and detection.   125 
Current surveillance analyses have regularly focused on age and birth cohorts 6.  Recent 126 
literature demonstrates associations showing that younger women in age groups 14-19 and 20-24 127 
has seen declines in HPV related sequalae, including intraepithelial cervical neoplasia grade 2+ 128 
and anogenital warts, in the years after FDA approval of the HPV vaccine in the United States8,9.  129 
Missing from current literature are statistical analyses demonstrating CIN 2+ incidence declines 130 
in racial/ethnic groups and women in low socioeconomic brackets.  This information is critical 131 
because data shows that as recently as 2017, racial minorities continue to have higher incidence 132 
rates of cervical cancer diagnoses & cervical cancer related mortality 16.  A sociodemographic 133 
analysis of incidence rate trends can help identify if vaccine access and population immunity is a 134 
homogenous phenomenon or if remaining incident cases are clustering around certain 135 
sociodemographic groups as a result of heterogenous vaccine distribution or utilization.  136 
Additionally, we expand upon the previous work of Niccolai et al. (2017) by extending the age-137 
based time series analysis of CIN 2+ incidence trends up until 2017 and by performing time series 138 
analyses of CIN 2+ incidence trends from 2008-2017 across race, ethnicity, and socioeconomic 139 
status. 140 
Methods 141 
The Emerging Infections Program has been collecting data on cervical intraepithelial 142 
neoplasia (CIN) since 2008 in conjunction with the Department of Public Health (DPH) of 143 
Connecticut.  Women who identified under the age of 21 were excluded from this analysis due to 144 
changes in clinical guidelines in 2012 which now recommend that women under age 21 do not 145 
undergo routine cervical cancer screening.  Population denominators used to calculate incidence 146 
rates were obtained through two different sources – the U.S. Census Bureau American Community 147 
Survey (ACS) and the Behavioral Risk Factor Surveillance System (BRFSS).   148 
The American Community Survey identified 411,624 women in Connecticut between the 149 
ages of 21-39.  Incidence rates were calculated by dividing case counts by the total population of 150 
women in CT who identify between the ages of 21-39.  To account for the fact that cervical cancer 151 
screening is a prerequisite for CIN 2+ diagnosis, the ACS denominators were adjusted by 152 
multiplier values using data from BRFSS.  This allowed incidence rate calculations to only include 153 
women who have undergone cervical cancer screenings.  BRFSS multiplier values were calculated 154 
for each year by dividing the number of women who self-reported as having a Pap smear in the 155 
past year by the total number of women.  Women who expressed uncertainty when asked if they 156 
had a Pap smear in the past year were excluded to avoid unintentional distortions of the numerator 157 
or denominator values when calculating the population adjustment multiplier value.  BRFSS data 158 
was only collected biannually.  For years without adjustment proportions, multiplier values were 159 
obtained by calculating the average of the multiplier value from the preceding and succeeding 160 
years.  161 
Change point analyses using negative binomial regressions were performed to identify 162 
best-fit models for CIN 2+ incidence rate trends stratified by race, ethnicity, and socioeconomic 163 
status.  Using U.S. census tract data for all 833 CT census tracts, CIN 2+ cases were counted and 164 
categorized by the following categories: census tracts where the percentage of people who identify 165 
as Black, Latino/Hispanic, or below the Federal Poverty Line (FPL) compose <5 % of the census 166 
tract population, > 5 % but < 10%, > 10% but < 20%, and > 20%.  Trends in declines were 167 
visualized by modeling both incidence rates (IRs) and incidence rate ratios (IRRs).  Incidence rate 168 
ratio values were calculated by using the incidence rate during the first year of follow-up (i.e. 169 
2008) as the reference value. Trends across sociodemographic factors by individual year could not 170 
be identified because the sample size in each category would decrease substantially, thereby 171 
sharply reducing power and allowing increased risk of type II error in the analysis.  In order to 172 
maintain substantial power, trends were categorized into age groups with separate models run for 173 
age groups 21-24, 25-29, 30-34, and 35-39.   174 
Changes in incidence of cervical neoplasia were tracked annually to account for HPV 175 
vaccine impact, both directly and indirectly (i.e. herd immunity).  Change-point models were used 176 
to identify if declines in CIN 2+ incidence varied by age group in either year of onset or rate of 177 
decline.  Change-point analyses were created using negative binomial regression models.  The 178 
outcome of interest for each model was the incidence rate of CIN 2+ per 100,000 person-years for 179 
each age group.  An alternative regression model was fit for each year during which data were 180 
collected (10 models total).  These models included intercept-only models and models that 181 
demonstrated steady linear declines in CIN+2 incidence rates from 2008-2017 after undergoing 182 
log transformations.  Optimal change-point models were identified by weights generated from 183 
Akaike criterion scores.  Higher weights were allocated to better fitting models.  Akaike scores 184 
estimate the quality of models used in statistical analysis while accounting for risks of underfitting 185 





Between 2008-2017 there were 17,605 cases of cervical intraepithelial neoplasia diagnosed 191 
as grade 2 or higher.  Annual incidence declined from 2,117 cases in 2008 to 1,320 cases in 2017 192 
(see Figure 1).   193 
 194 
Figure 1: Annual Incidence Count of CIN 2+ Diagnoses in Connecticut 195 
When U.S. census tract data was used to stratify CIN 2+ incidence rate ratio trends by race, 196 
ethnicity, and socioeconomic status, statistically significant declines were observed in individuals 197 
ages 21-24.  This held true across all categories of census tract populations identifying as Black 198 
(see figure 2), census tract populations identifying as Hispanic (see figure 3), and census tract 199 
populations identifying as below the federal poverty line (i.e. < 5%, between 5 and 10%, between 200 
10% and 20%, and greater than 20%) (see figure 4).  Incidence rate declines were also observed 201 
in age groups 25-29, 30-34, and 35-39.  However, unlike in the 21-24-year age group, declines 202 
were not consistent across all census tract categories.  In fact, incidence rate increases were 203 
observed across census tracts where more than 10% of individuals identify as Black, Latinx, or 204 




















Annual Incidence of CIN+2 Diagnoses
confidence intervals for incidence rate ratios included the null value of 1.00.  Statistically 206 
significant declines were also observed in age group 21-24 across race, ethnicity, and 207 
socioeconomic status when incidence rate ratios were estimated among screened women. 208 
Similarly, when analysis was adjusted by BRFSS data the trends observed and predicted for 209 
incidence rates of CIN 2+ in age groups 25-29, 30-34, and 35-39 was found not to be statistically 210 
significant since 95% confidence intervals included the null value of 1.00 (see figures 5-7).   211 
 212 





Identifying as Black 
IRR Decline 
After 10 Years 
IRR Decline 95% 
Confidence Interval 
Lower Limit  
IRR Decline 95% 
Confidence Interval 
Upper Limit  
< 5% 76% 67% 82% 
< 5% but < 10% 75% 66% 81% 
< 10% but < 20% 77% 64% 85% 









After 10 Years 
IRR Decline 95% 
Confidence Interval 
Lower Limit  
IRR Decline 95% 
Confidence Interval 
Upper Limit  
< 5% 75% 63% 83% 
< 5% but < 10% 76% 65% 84% 
< 10% but < 20% 76% 68% 82% 






Identifying as Below 
FPL 
IRR Decline 
After 10 Years 
IRR Decline 95% 
Confidence Interval 
Lower Limit  
IRR Decline 95% 
Confidence Interval 
Upper Limit  
< 5% 76% 71% 80% 
< 5% but < 10% 77% 69% 83% 
< 10% but < 20% 71% 64% 77% 
< 20%  78% 70% 84% 
 216 
 217 
Figure 2: CIN 2+ Incidence Rate Trends – % Population Black – Total Population 218 
Figure 3: CIN 2+ Incidence Rate Trends – % Population Hispanic/Latino. – Total Population 219 
Figure 4: CIN 2+ Incidence Rate Trends – % Population Below FPL – Total Population 220 





Identifying as Black 
IRR Decline 
After 10 Years 
IRR Decline 95% 
Confidence Interval 
Lower Limit  
IRR Decline 95% 
Confidence Interval 
Upper Limit  
< 5% 67% 53% 77% 
< 5% but < 10% 66% 55% 75% 
< 10% but < 20% 69% 52% 80% 









After 10 Years 
IRR Decline 95% 
Confidence Interval 
Lower Limit  
IRR Decline 95% 
Confidence Interval 
Upper Limit  
< 5% 67% 60% 72% 
< 5% but < 10% 68% 52% 79% 
< 10% but < 20% 68% 57% 76% 






Identifying as Below 
FPL 
IRR Decline 
After 10 Years 
IRR Decline 95% 
Confidence Interval 
Lower Limit  
IRR Decline 95% 
Confidence Interval 
Upper Limit  
< 5% 67% 56% 75% 
< 5% but < 10% 69% 59% 76% 
< 10% but < 20% 62% 52% 69% 
< 20%  70% 58% 79% 
Figure 5: CIN 2+ Incidence Rate Trends – % Population Black – Screening Population 224 
Figure 6: CIN 2+ Incidence Rate Trends – % Population Latino/Hispanic – Screening Population 225 
Figure 7: CIN 2+ Incidence Rate Trends – % Population Below FPL. – Screening Population 226 
When using total population, significant declines in CIN 2+ incidence rate ratios were 227 
found in women ages 21-24 across all area based measures of sociodemographic characteristics: 228 
% census tract population identifying as Black < 5% [76% decline in IRR, 95% CI (67%, 82%)], 229 
% census tract population identifying as Black between 5% and 10%  [75% decline in IRR, 95% 230 
CI (66%, 81%)], % census tract population identifying as Black between 10% and 20% [77% 231 
decline in IRR, 95% CI (64%, 85%)], % census tract population identifying as Black greater than 232 
20% [75% decline in IRR, 95% CI (67%, 81%)]. % census tract population identifying as Hispanic 233 
< 5% [75% decline in IRR, 95% CI (63%, 83%)], % census tract population identifying as Hispanic 234 
between 5% and 10%  [76% decline in IRR, 95% CI (65%, 84%)], % census tract population 235 
identifying as Hispanic between 10% and 20% [76% decline in IRR, 95% CI (68%, 82%)], % 236 
census tract population identifying as Hispanic greater than 20% [73% decline in IRR, 95% CI 237 
(66%, 78%)].  % census tract population identifying as below the FPL < 5% [76% decline in IRR, 238 
95% CI (71%, 80%)], % census tract population identifying as below the FPL between 5% and 239 
10%  [77% decline in IRR, 95% CI (69%, 83%)], % census tract population identifying as below 240 
the FPL between 10% and 20% [71% decline in IRR, 95% CI (64%, 77%)], % census tract 241 
population identifying as below the FPL greater than 20% [78% decline in IRR, 95% CI (70%, 242 
84%)].  Changes in incidence rate ratios for individuals who identify between the ages of 27-39 243 
were not statistically significant.   244 
When using adjusted BRFSS data, significant declines in CIN +2 incidence rate ratios were 245 
found in women ages 21-24 across all sociodemographic characteristics: % census tract population 246 
identifying as Black < 5% [67% decline in IRR, 95% CI (53%, 77%)], % census tract population 247 
identifying as Black between 5% and 10%  [66% decline in IRR, 95% CI (55%, 75%)], % census 248 
tract population identifying as Black between 10% and 20% [69% decline in IRR, 95% CI (52%, 249 
80%)], % census tract population identifying as Black greater than 20% [66% decline in IRR, 95% 250 
CI (54%, 75%)]. % census tract population identifying as Hispanic < 5% [67% decline in IRR, 251 
95% CI (60%, 72%)], % census tract population identifying as Hispanic between 5% and 10%  252 
[68% decline in IRR, 95% CI (52%, 79%)], % census tract population identifying as Hispanic 253 
between 10% and 20% [68% decline in IRR, 95% CI (57%, 76%)], % census tract population 254 
identifying as Hispanic greater than 20% [63% decline in IRR, 95% CI (53%, 71%)].  % census 255 
tract population identifying as below the FPL < 5% [67% decline in IRR, 95% CI (56%, 75%)], 256 
% census tract population identifying as below the FPL between 5% and 10%  [69% decline in 257 
IRR, 95% CI (59%, 76%)], % census tract population identifying as below the FPL between 10% 258 
and 20% [62% decline in IRR, 95% CI (52%, 69%)], % census tract population identifying as 259 
below the FPL greater than 20% [70% decline in IRR, 95% CI (58%, 79%)].  Changes in incidence 260 
rate ratios for individuals who identify between the ages of 27-39 were not statistically significant.   261 
Significant declines in CIN +2 incidence rate ratios for the total population were found in 262 
women in the following age groups: age 21 [85% decline in IRR, 95% CI (78%, 89%)], age 22 263 
[81% decline in IRR, 95% CI (71%, 87%)], age 23 [75% decline in IRR, 95% CI (67%, 81%)], 264 
age 24 [60% decline in IRR, 95% CI (47%, 70%)], age 25 [44% decline in IRR, 95% CI (27%, 265 
57%)], and age 26 [35% decline in IRR, 95% CI (10%, 54%)] (see figure 8).  Change point analysis 266 
show that declines in incidence of CIN +2 cases in age group 21-22 begin in 2010 (i.e. 3rd year of 267 
surveillance period).  Declines in incidence rate of CIN 2+ in age group 23-25 begin in 2012 (i.e. 268 
4th year of data collection).  Declines in individuals age 26 are predicted to begin in 2011 (i.e. 3rd 269 
year of data collection).  Changes in incidence rate ratios for individuals who identify between the 270 
ages of 27-39 were not statistically significant.   271 
When incidence rates were estimated among the screened population, significance in CIN 272 
+2 incidence rate declines held only in individuals ages 21-25 (see figure 9).  When adjusted by 273 
BRFSS data the following declines in CIN +2 incidence rate ratios were observed: age 21 [80% 274 
decline in IRR, 95% CI (72%, 85%)], age 22 [74% decline in IRR, 95% CI (65%, 81%)], age 23 275 
[66% decline in IRR, 95% CI (54%, 75%)], age 24 [46% decline in IRR, 95% CI (29%, 59%)], 276 
and age 25 [30% decline in IRR, 95% CI (1%, 50%)].  Change point analysis predict onset of 277 
incidence rate declines in each age group at the following time points: age 21 (year 2 – 2010), age 278 
22 (year 2 – 2010), age 23 (year 4 – 2012), age 24 (year 4 – 2012), age 25 (year 7 – 2015).  279 
 280 
Figure 8: CIN 2+ Incidence Rate Trends – Total Population – U.S. Census Tract Data 281 
 282 
 283 
Figure 9: CIN 2+ Incidence Rate Trends – Screening Population – BRFSS Data  284 
Discussion 285 
 Our results showed a statistically significant decline in incidence rate per 100,000 person-286 
years of cervical intraepithelial neoplasia diagnoses of grade 2 or higher in individuals age 21-26 287 
from 2008-2017.  When incidence rates were estimated among the screened population, incidence 288 
rate declines remained statistically significant for individuals ages 21-25.   289 
When incidence rates of CIN 2+ are stratified by race, ethnicity, and socioeconomic status 290 
these declines are shown to be statistically significant in the age group 21-24 across all levels of 291 
each variables.  Statistically significant declines were observed regardless of the percentage of the 292 
population in a given census tract that identified with each sociodemographic variable (i.e. < 5%, 293 
> 5% and < 10%, > 10% and < 20%, and > 20%).  The presence of declines of CIN 2+ incidence 294 
in areas with varying population sizes of Latina women, Black women, and women living below 295 
the poverty lines suggests that all three sociodemographic communities are showing similar 296 
declines since introduction of HPV vaccination in 2006.  Additionally, older age cohorts (i.e. 25-297 
29, 30-34, and 35-39) also display declines in CIN +2 incidence rates across racial and 298 
socioeconomic identities.  However, these declines are only observed in census tracts where less 299 
than 10% of individuals identify as Black, Latinx, or below the federal poverty line and they are 300 
not statistically significant based on current data.   301 
In the oldest age cohort (i.e. 35-39 yr-olds) observed and predicted incidence rate trends 302 
revealed that incidence of CIN 2+ was increasing in census tracts where more than 10% of 303 
individuals identified as Black, Latinx, or below the federal poverty line.  This may be attributable 304 
to a variety of reasons.  For example, these census tracts may be seeing an expansion of healthcare 305 
services in succeeding years, thereby allowing more women to undergo cervical cancer screenings 306 
which would identify these precancerous lesions.  These older women would also have been 307 
outside of the age group for which the HPV vaccination schedule was originally recommended, 308 
even when looking back to 2006 when they were between the ages of 24-28.  Alternatively, these 309 
rising trends may be attributable to behavioral changes (e.g. changes in sexual behavior) 310 
centralized in these census tracts.  Future field research, medical history collection of cases, and 311 
longitudinal follow-up will be necessary to identify risk factors for these trends.   312 
This same time period saw vaccine coverage for adolescent youth ages 13-15 in 313 
Connecticut fluctuate between 25.8% and 47.1% according to the National Immunization Survey 314 
– Teens 16 reported by the CDC.  Rising trends in HPV coverage in adolescents in CT should lead 315 
to substantial declines in CIN +2 diagnoses in older age groups in succeeding years. 316 
The strength of this analysis is that population level trends provide information on the 317 
direct impact of HPV vaccination and the indirect effect of herd immunity.  The continued decline 318 
of CIN +2 incidence rate trends among the screened populations indicates that the decrease in 319 
precancerous cervical lesions cannot be adequately explained by changes in clinical guidelines 320 
which now recommend more infrequent cervical cancer screenings for cost-effective reasons in 321 
women below 30 (i.e. every 3 years instead of annually).   322 
However, this analysis should be acknowledged with several limitations.  As an ecological 323 
study this analysis is limited to the population level variables available in the data collected through 324 
HPV-IMPACT.  Data collection did not account for individual level information regarding 325 
whether or not cases were previously vaccinated for HPV. Moreover, BRFSS data was only 326 
provided biannually and was collected through self-report. In other words, women who may have 327 
gone to a primary care clinician or gynecologist may have mistaken other gynecological 328 
procedures for a Pap smear and mistakenly reported yes to having undergone a Pap smear in the 329 
past year.  This would result in an overestimation of the denominator multiplier and 330 
underestimation of CIN 2+ incidence rates.  That said, a benefit of self-report data is that it can 331 
account for cases not identifiable through insurance claims data, such as undocumented women 332 
who may undergo cervical cancer screenings at free clinics without traceable claims data to 333 
confirm the procedure.  Lastly, this data does not discern between cisgender women and 334 
transgender men or gender non-conforming individuals, thereby leaving room for missing data 335 
from key demographics.   336 
This analysis contributes to growing literature assessing the impact of HPV vaccination 337 
coverage on the incidence of HPV related sequalae, including anogenital warts, pre-cancerous 338 
lesions, and cervical cancer with a special focus on trends by area-based measures of 339 
sociodemographic characteristics.  Continued longitudinal analysis should be performed to assess 340 
if CIN + 2 diagnoses decline in older age groups and to advocate for further HPV vaccination 341 
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